Engineering bacterium for expressing recombinant fibronectin as well as construction method and application of engineering bacterium
By designing specific encoding nucleic acids and constructing expression vectors, the secretion efficiency and expression amount of recombinant fibronectin is improved. By optimizing the purification process, the difficulties in the expression and purification process are solved, and high-efficiency and low-cost high-active recombinant fibers are achieved. The preparation of conjunctin has enhanced its potential in biomedical research and clinical applications.
Patent Information
- Application Number
- CN202411448483.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-16
- Publication Date
- 2024-11-26
AI Technical Summary
The expression level of recombinant fibronectin is insufficient, the folding and assembly is difficult, the purification process is complex and costly, which affects its widespread use in biomedical research and clinical applications.
Design specific recombinant fibronectin-encoded nucleic acid sequences, construct expression vectors and engineered bacteria, use Pichia cerevisiae and pPIC9K plasmid to improve secretion efficiency and expression, and use purification processes of affinity chromatography and molecular sieve chromatography to optimize buffer and Flow rate to improve purification efficiency.
The efficient and low-cost preparation of highly active recombinant fibronectin has been achieved, which has improved its potential in biomedical research and clinical applications.
Smart Images

Figure CN119020367A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of genetic engineering, and relates to an engineering bacterium expressing recombinant fibronectin, a construction method and application thereof. Background Art
[0002] Fibronectin (FN) is a high molecular weight glycoprotein and one of the main components of the extracellular matrix. As an important adhesion molecule and macromolecular glycoprotein, it is widely present in plasma, various cell surfaces and cell matrix. Fibronectin contains six functional domains and an RGD sequence. Studies have shown that the third domain of fibronectin plays an important role in regulating cell adhesion, migration activities, and wound repair and healing. Recombinant fibronectin (rFN) is a fibronectin synthesized in vitro through bioengineering technology. It simulates the structure and function of fibronectin in the human body. Compared with fibronectin extracted from natural sources, recombinant fibronectin has higher purity and lower risk of pathogen contamination, so it has significant advantages in biomedical research and clinical applications.
[0003] Recombinant fibronectin usually utilizes genetic engineering technology to insert the gene encoding fibronectin into microorganisms (such as Escherichia coli or yeast) or mammalian cells, and fibronectin is expressed and secreted by these host cells. Then, the target protein is extracted and purified from the culture medium through a series of purification steps, such as affinity chromatography, ion exchange chromatography, etc. For example, CN111004319A discloses recombinant human collagen and its application, wherein the recombinant human collagen comprises, from the amino end, an amino-terminal affinity purification tag, a mature peptide chain of the α2 chain of human type I collagen, and a carboxyl-terminal affinity purification tag, wherein the amino-terminal affinity purification tag is a Flag tag, and the carboxyl-terminal affinity purification tag is a 6His tag, and the recombinant human collagen is extracted and purified from the fermentation broth by adsorption of Ni-NTA His·Bind resin and Anti-Flag affinity purification gel.
[0004] The preparation of recombinant fibronectin is a complex process. Although the development of genetic engineering technology has made this process more feasible, there are still some challenges and problems. For example, in some expression systems, the expression level of fibronectin may not be sufficient to meet the needs of large-scale production. Low expression levels may lead to insufficient yields and increase production costs. Fibronectin is a large molecular protein with complex domains and disulfide bonds, which makes it challenging to fold and assemble correctly in vitro. Incorrect folding may lead to loss of activity or the formation of insoluble aggregates. Fibronectin undergoes a variety of post-translational modifications in vivo, such as glycosylation and phosphorylation. These modifications are essential for its function. In in vitro expression systems, these modifications may be incomplete, thus affecting the function and stability of the protein. The purification process of fibronectin may be complex and costly.
[0005] In summary, developing a method for preparing recombinant fibronectin and achieving efficient and low-cost preparation of highly active recombinant fibronectin are of great significance for the application field of recombinant fibronectin. Summary of the invention
[0006] In view of the deficiencies in the prior art and actual needs, the present invention provides an engineered bacterium expressing recombinant fibronectin and a construction method and application thereof, designs a specific nucleic acid encoding recombinant fibronectin, further constructs the engineered bacterium, improves the secretion efficiency and expression level of the recombinant protein, and designs a purification process, in order to achieve efficient and low-cost preparation of highly active recombinant fibronectin.
[0007] To achieve this object, the present invention adopts the following technical solutions:
[0008] In a first aspect, the present invention provides a nucleic acid encoding a recombinant fibronectin, wherein the sequence of the nucleic acid encoding the recombinant fibronectin includes the sequence shown in SEQ ID NO.1.
[0009] SEQ ID NO.1:
[0010] .
[0011] In the present invention, a novel nucleic acid encoding recombinant fibronectin is designed, which is beneficial to improving the expression amount and secretion efficiency in the host, and can be used to construct vectors and engineered bacteria for expressing recombinant fibronectin.
[0012] In a second aspect, the present invention provides a recombinant vector, wherein the recombinant vector contains the nucleic acid encoding the recombinant fibronectin described in the first aspect.
[0013] Preferably, the starting vector of the recombinant expression vector includes a pPIC9K vector.
[0014] In the present invention, pPIC9K plasmid is used as a vector, which can be integrated into the host genome, contains an alpha factor secretion signal peptide sequence, and can secrete and express foreign protein genes. The vector also contains the promoter and transcription terminator of the alcohol oxidase-1 (AOX1) gene, and the two are separated by a multiple cloning site (MCS). The secretory expression of the recombinant protein is controlled by the AOX1 promoter and can be induced by methanol.
[0015] In a third aspect, the present invention provides an engineered bacterium expressing recombinant fibronectin, wherein the engineered bacterium expresses recombinant fibronectin; the sequence of the nucleic acid encoding the recombinant fibronectin includes the sequence shown in SEQ ID NO.1.
[0016] Preferably, the starting strain of the engineered bacteria includes Pichia pastoris.
[0017] Preferably, the Pichia pastoris comprises Pichia pastoris GS115.
[0018] Preferably, the nucleic acid encoding the recombinant fibronectin is located in a recombinant expression vector.
[0019] Preferably, the starting vector of the recombinant expression vector includes a pPIC9K vector.
[0020] In the present invention, Pichia pastoris is used as a eukaryotic expression host, and a pPIC9K vector is used to express the designed recombinant fibronectin encoding nucleic acid, which can improve the secretion efficiency and expression amount of the recombinant protein.
[0021] Preferably, the copy number of the nucleic acid encoding the recombinant fibronectin in the engineered bacteria is 4 to 6 copies.
[0022] In a fourth aspect, the present invention provides a method for constructing an engineered bacterium expressing recombinant fibronectin according to the third aspect, the method comprising:
[0023] The encoding nucleic acid of the recombinant fibronectin is inserted into the starting vector to obtain the recombinant vector, and the recombinant vector is introduced into the starting strain to obtain the engineered bacteria expressing the recombinant fibronectin.
[0024] It is understood that the common genetic engineering methods in the art, such as constructing expression vectors, preparing competent cells, and transduction, are applicable to the present invention as long as they can implement the genetic engineering strategy of the present invention.
[0025] In a fifth aspect, the present invention provides use of the engineered bacteria expressing recombinant fibronectin described in the third aspect in producing recombinant fibronectin.
[0026] In a sixth aspect, the present invention provides a method for producing recombinant fibronectin, the production method comprising:
[0027] The engineered bacteria expressing the recombinant fibronectin described in the third aspect are fermented and cultured, the fermentation liquid is collected, and the product is purified to obtain the recombinant fibronectin.
[0028] Preferably, the product purification treatment comprises sequentially performing affinity chromatography and molecular sieve chromatography on the fermentation broth.
[0029] Preferably, the filler material of the affinity chromatography comprises Ni-IDA and / or Ni-NTA.
[0030] Preferably, the affinity chromatography buffer comprises NTA-5 buffer and NTA-400 buffer, wherein the NTA-5 buffer contains 4.5-5.5 mM imidazole, 19-21 mM Tris and 140-160 mM NaCl, and the pH is 7-9.5 (preferably 8.5-9.5), and the NTA-400 buffer contains 380-420 mM imidazole, 19-21 mM Tris and 140-160 mM NaCl, and the pH is 7-9.5 (preferably 8.5-9.5).
[0031] Preferably, the affinity chromatography comprises the following steps:
[0032] 1) flushing the column with NTA-5 buffer until the pH, UV, and Cond detection baselines are stable;
[0033] 2) Loading the sample, collecting the flow-through components during the loading process, and detecting the purity and content of the target protein;
[0034] 3) Wash with buffer (NTA-5: 94% to 98% and NTA-400: 2% to 6%) until the UV detection value drops to the initial value;
[0035] 4) Use buffer (NTA-5: 24% to 26% and NTA-400: 74% to 76%) to elute the target protein and collect the eluted fractions.
[0036] Preferably, the sample injection speed is 55-65 cm / h, and the injection speed of each buffer solution is 80-100 cm / h.
[0037] Preferably, the filler of the molecular sieve chromatography includes at least one of dextran bead gel, agarose gel, polyacrylamide gel or Sephacryl gel.
[0038] Preferably, the buffer for the molecular sieve chromatography contains 120-130 mM Na2HPO4 and 14-16 mM NaCl, and the pH is 7-9.5 (preferably 8.5-9.5).
[0039] Preferably, the molecular sieve chromatography comprises the following steps:
[0040] 1) flushing the column with buffer until the pH, UV, and Cond detection baselines are stable;
[0041] 2) Loading the sample, collecting the flow-through components during the loading process, and detecting the purity and content of the target protein;
[0042] 3) Use buffer for elution, elute the target protein and salt ions in sequence according to their molecular weight, and collect the eluted components.
[0043] Preferably, the sample injection speed is 55-65 cm / h, and the injection speed of each buffer solution is 80-100 cm / h.
[0044] The present invention optimizes the system flow rate, simplifies some operations, and improves purification efficiency; optimizes the pH value of the buffer, is beneficial to the stability of the target protein, and slightly improves the protein purification effect.
[0045] Compared with the prior art, the present invention has the following beneficial effects:
[0046] The present invention designs a novel nucleic acid encoding recombinant fibronectin, which is beneficial to improving the expression amount and secretion efficiency in the host, further constructs an engineered bacterium expressing recombinant fibronectin, realizes efficient expression and secretion of recombinant fibronectin, and designs a purification process, utilizes affinity chromatography purification and molecular sieve chromatography desalting, and cooperates to obtain high-purity and high-activity recombinant fibronectin. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 This is the result of transformant sequencing identification;
[0048] Figure 2 This is a graph showing protein expression in the supernatant of fermentation broth of strains with different copy numbers;
[0049] Figure 3 The electrophoresis diagrams of samples at each stage of affinity chromatography process;
[0050] Figure 4 The electrophoresis diagrams of samples at each stage of the desalting process;
[0051] Figure 5 This is a diagram of the purification results before and after optimization;
[0052] Figure 6 This is the result of the cell scratch experiment with recombinant fibronectin. DETAILED DESCRIPTION
[0053] The technical solution of the present invention is further described below in conjunction with the accompanying drawings and through specific implementation methods. However, the following examples are only simplified examples of the present invention and do not represent or limit the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.
[0054] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.
[0055] In the present invention, in response to the demand for efficient and low-cost preparation of high-quality recombinant fibronectin, an engineered bacterium expressing recombinant fibronectin and a production and purification process are designed and constructed to achieve efficient production of recombinant fibronectin with high activity.
[0056] Example 1
[0057] In this example, an engineered bacterium expressing recombinant fibronectin was constructed.
[0058] The recombinant fibronectin coding region sequence was redesigned, and a signal peptide and a fusion His tag were added to design the overall expression sequence (SEQ ID NO.1).
[0059] The expression sequence was inserted into the pPIC9K plasmid cloning site (MCS) to obtain the recombinant plasmid (commissioned to Suzhou Biotechnology Co., Ltd. for synthesis).
[0060] The recombinant plasmid was transfected into Pichia pastoris GS115 to prepare Pichia pastoris electroporation competent cells and electroporation transformation. The preparation of Pichia pastoris electroporation competent cells was based on the method of (Condensed protocol for competent cell preparation and transformation of the methylotrophic yeast Pichia pastoris. Biotechniques. 2005 January. 38 (1): 44-48.).
[0061] 1. Streak the competent Pichia yeast on a YPD (Yeast Extract Peptone Dextrose Medium) solid medium plate and culture in a 30°C incubator for two days;
[0062] 2. Pick a healthy single colony and place it in YPD liquid medium, and culture it in a shaking incubator at 30°C overnight;
[0063] 3. Transfer an appropriate amount of overnight culture solution to a 1L Erlenmeyer flask containing 100mL of liquid YPD to control the initial OD 600 0.15-0.2, 30℃ shaking incubator;
[0064] 4. To OD 600 The concentration was 0.8-1.0, and the cells were collected by centrifugation at 500×g for 5 min at room temperature (can be 20-35°C);
[0065] 5. Resuspend the cells with 9 mL of ice-cold BEDS solution (consisting of 10 mmol / L NaOH (pH 8.3), 3% (v / v) ethylene glycol, 5% (v / v) dimethyl sulfoxide (DMSO) and 1 mol / L sorbitol), and add 1 mL of 1 M dithiothreitol (DTT) solution dropwise, and incubate at 30 °C on a shaker (100 rpm) for 5 min;
[0066] 6. Collect the cells by centrifugation at 500 × g for 5 min at room temperature and resuspend the cells in 2 mL of ice-cold BEDS;
[0067] 7. Aliquot the resuspended cells into pre-cooled 1.5 mL centrifuge tubes, 50 μL per tube, and quickly store the prepared competent cells in a -80 °C refrigerator;
[0068] 8. Mix 100 ng circular or 2 μg linear plasmid DNA with 50 μL competent cells and incubate the mixture on ice for 2 min;
[0069] 9. Pipette the mixture of competent cells and plasmid into a 2mm pre-cooled electroporation cup on ice, wipe off the water on the cup body, and then place it in the groove of the electroporator, and pulse at 1.5kV and 5.0s;
[0070] 10. Immediately add 1 mL of a mixed solution of YPD: 1 M sorbitol in a volume ratio of 1:1, blow the cells in the electric transfer cup evenly, then aspirate the solution and place it in a 1.5 mL sterile centrifuge tube, incubate at 30°C on a shaker for 1 h, spread on MD agar plate medium containing G418 sulfate, and culture at 30°C for 5 days until white Pichia colonies appear.
[0071] The transformation plates were placed in a 30°C incubator for 3 days, and single colonies grew on all plates. Ten single colonies were picked from each transformation plate and cultured in liquid YPD medium containing a final concentration of 125 μg / mL G418 sulfate for 16 hours, and then an appropriate amount of bacterial liquid was taken to extract its genomic DNA, using the detection primers:
[0072] Forward primer: 5′-CGACTGGTTCCAATTGACAAGC;
[0073] Reverse primer: 3′-GACCGGTCTTCTCGTAAGTGC.
[0074] PCR detection was performed, and the PCR reaction conditions were: pre-denaturation at 94°C for 5 min; denaturation at 94°C for 30 s, annealing at 63°C for 30 s, extension at 72°C for 2 min, 35 cycles; extension at 72°C for 5 min; Beijing Qingke Biotechnology Co., Ltd. was commissioned to sequence the PCR products and screen out the correct recombinant fibronectin expression strains. The sequencing identification results of five transformants are shown in Figure 1;
[0075] Screening of multi-copy recombinant bacteria: ppic9k contains the bacterial Kan gene, which confers geneticin (G418) resistance to Pichia pastoris. The level of geneticin resistance depends mainly on the number of integrated genes. After a single copy of ppic9k is integrated into the Pichia pastoris genome, it confers a geneticin resistance level of about 0.25 mg / mL to Pichia pastoris. Multi-copy integration of the vector can increase the level of geneticin resistance from 0.5 mg / mL (1-2 copies) to 4.0 mg / mL (7-12 copies). Therefore, the number of multi-copy target genes contained in the clone can be inferred from the high resistance to geneticin.
[0076] YPD plates were prepared with geneticin concentrations of 0, 0.25, 0.5, 0.75, 1.0, 1.5, 1.75, 2.0, 3.0 and 4.0 mg / mL, respectively. Successfully identified transformants were streaked on the plates using a sterilized toothpick and cultured at 30°C for 2 days.
[0077] The growth status of each transformant on different concentrations of Geneticin plates was analyzed, and one transformant that could grow normally on 3.0 mg / mL Geneticin plates was screened out, which was a multi-copy recombinant strain named GS115-FN3. There were four other strains that could only grow normally on 0.5 mg / mL Geneticin plates.
[0078] They were named Gs115-FN1, Gs115-FN2, Gs115-FN4 and Gs115-FN5 respectively.
[0079] Example 2
[0080] In this example, recombinant fibronectin was expressed.
[0081] The secretory expression plasmid pPIC9K contains an alpha factor secretory signal peptide sequence, which can secrete and express foreign protein genes; the vector also contains the promoter and transcription terminator of the alcohol oxidase-1 (AOX1) gene, which are separated by a multiple cloning site (MCS), and the coding sequence of recombinant fibronectin is inserted therein. Therefore, the secretory expression of recombinant fibronectin is controlled by the AOX1 promoter and can be induced by methanol. The method for secretory expression of recombinant fibronectin is as follows.
[0082] Prepare YPD, BMGY and BMMY culture media respectively (by mass percentage):
[0083] BMGY medium: 1% yeast extract, 2% peptone, 1.34% YNB, 1% glycerol and 10% 1M PBS (pH=6.0), the balance is water;
[0084] BMMY medium: 1% yeast extract, 2% peptone, 1.34% YNB, 1% methanol and 10% 1M PBS (pH=6.0), the balance is water;
[0085] YPD solid medium: 1% yeast extract, 2% peptone, 2% glucose and 2% agar powder;
[0086] First, the engineered bacteria expressing recombinant fibronectin constructed in Example 1 were streaked on YPD solid culture medium, placed in a 30°C incubator for 24 hours to activate the strain; a single colony was picked up and placed in 10 mL of BMGY culture medium, and placed in a 30°C shaker for 24 hours; the OD value of the bacterial solution was detected, an appropriate amount of the bacterial solution was centrifuged at a speed of 5000 rpm for 5 minutes, the bacteria were resuspended in BMMY culture medium, and the washing was repeated once; the washed bacteria were transferred to 50 mL of BMMY culture medium, and 1% methanol was added, and the bacteria were placed in a 30°C shaker for 5 days to start fermentation, and 1% methanol was added every 24 hours; the fermentation broth was centrifuged at high speed, and the supernatant was taken for electrophoresis detection; and then purified by affinity chromatography and other methods to obtain pure recombinant fibronectin;
[0087] Agarose gel electrophoresis was used to detect the protein expression in the supernatant of each fermentation broth. Figure 2 As shown, the expression level of the high-copy strain was significantly greater than that of the single-copy strain.
[0088] Example 3
[0089] This example is about the extraction and purification of recombinant fibronectin.
[0090] GS115-FN3 was fermented and cultured according to the method in Example 2. The supernatant after centrifugation of the fermentation broth was taken and filtered using a 0.1 μm vacuum filtration bottle to remove impurities with larger particle sizes and reduce damage to the chromatography column; the filtrate was concentrated 3 times using a 10 kd ultrafiltration tube to reduce the affinity chromatography purification loading time; the pH value and salt concentration of the imidazole buffer were optimized to improve the stability of the recombinant fibronectin sample in the buffer; during the purification process, the loading ratio of NTA-5 and NTA-400 buffers was adjusted, and an imidazole buffer of any concentration of 5-400 mM could be prepared through the premixer of the purifier, which was directly used in the equilibration, washing and elution steps of affinity chromatography purification, eliminating the time for preparing imidazole buffers of different concentrations.
[0091] 1L fermentation broth was centrifuged at 1000×g for 10 min, and the supernatant was collected; the supernatant was filtered using a 0.1μm vacuum filtration bottle; the filtrate was concentrated 3 times using a 10kd ultrafiltration tube; about 300mL of pretreated sample was obtained, and then affinity chromatography purification and molecular sieve desalting were performed.
[0092] The affinity chromatography purification steps are as follows:
[0093] Sample: pre-treatment liquid of recombinant fibronectin fermentation broth supernatant;
[0094] Affinity chromatography column: NmLOAD 50 / 200-NW Rose Ni FF, purchased from Suzhou Nanomicrobiology Technology Co., Ltd.;
[0095] Protein purification instrument: Saipu Biotechnology Co., Ltd.;
[0096] Experimental reagents:
[0097] NTA-5 buffer: 5 mM imidazole, 20 mM Tris, and 150 mM NaCl, adjusted to pH 9.0 with concentrated HCl;
[0098] NTA-400 buffer: 400 mM imidazole, 20 mM Tris, and 150 mM NaCl, adjusted to pH 9.0 with concentrated HCl;
[0099] Experimental steps:
[0100] 1) Wash the column with NTA-5 buffer at a rate of 90 cm / h (30 mL / min) for 3 CV until the pH, UV, and Cond detection baselines are stable;
[0101] 2) Load the sample at a rate of 60 cm / h (20 mL / min) and collect the flow-through components during the loading process;
[0102] 3) Wash with (NTA-5: 96.2% and NTA-400: 3.8%) for 3CV at a speed of 90 cm / h to wash out the unbound materials until the UV detection value drops to the initial value;
[0103] 4) Elution was performed at a speed of 90 cm / h with (NTA-5: 25.3% and NTA-400: 74.7%) for 3CV to elute the target protein and collect the eluted fractions;
[0104] 5) Elute with NTA-400 buffer at a speed of 90 cm / h for 3CV to elute all the proteins on the column;
[0105] 6) Wash the column with at least 2 CV of 1 M NaOH at a speed of 60 cm / h to remove residual contaminants in the packed column, such as lipids, endotoxins, nucleic acids, etc.;
[0106] 7) Wash the column with 5-10 CV of distilled water at a rate of 60 cm / h until the pH of the effluent is neutral and Cond is close to 0 to remove 1 M NaOH;
[0107] 8) Wash and store with 3CV of 20% ethanol at a speed of 60cm / h to prevent microbial growth.
[0108] The steps of molecular sieve desalination are as follows:
[0109] Sample: Recombinant fibronectin affinity purified sample;
[0110] Molecular sieve chromatography column: NmLOAD 50 / 400-NW Dex G-25F, purchased from Suzhou Nanomicrobiology Technology Co., Ltd.;
[0111] Protein purification instrument: Saipu Biotechnology Co., Ltd.;
[0112] Experimental reagents: Desalting buffer: 125mM Na2HPO4, 15mM NaCl, pH adjusted to 9.0 with 1M NaH2PO4;
[0113] Experimental steps:
[0114] 1) Flush the column with desalting buffer for 3 CV at a speed of 90 cm / h until the pH, UV, and Cond detection baselines are stable;
[0115] 2) Load the sample at a speed of 60 cm / h, collect the flow-through components during the loading process, and detect the purity and content of the target protein;
[0116] 3) Elute with desalting buffer at a speed of 90 cm / h for 3CV, elute the target protein and salt ions in sequence according to their molecular weight, and collect the eluted fractions;
[0117] 4) Wash the column with at least 2 CV of 1 M NaOH at a rate of 60 cm / h to remove residual contaminants in the packed column;
[0118] 5) Wash the column with 5-10 CV of distilled water at a rate of 60 cm / h until the pH of the effluent is neutral and Cond is close to 0 to remove 1 M NaOH;
[0119] 6) Wash and store with 3CV of 20% ethanol at a speed of 60cm / h to prevent microbial growth.
[0120] Affinity chromatography procedure results ( Figure 3 ) showed that the recombinant fibronectin could be eluted in a concentrated manner.
[0121] Desalination process results ( Figure 4 ) showed that the protein peak and the salt peak could be separated, and the conductivity of the protein sample was significantly reduced from 16ms / cm to 0.5ms / cm, with a significant desalting effect.
[0122] Example 4
[0123] This example is about the extraction and purification of recombinant fibronectin.
[0124] The fermentation process was as in Example 3.
[0125] The following NTA buffers all have a pH of 8:
[0126] 1) Wash the column with NTA-5 buffer for 3 CV at a rate of 60 cm / h (30 mL / min) until the pH, UV, and Cond detection baselines are stable;
[0127] 2) Load the sample at a rate of 60 cm / h (20 mL / min) and collect the flow-through components during the loading process;
[0128] 3) Wash with NTA-20 at a speed of 60 cm / h for 3CV to wash out unbound materials until the UV detection value drops to the initial value;
[0129] 4) Wash the impurities with NTA-100 at a speed of 60 cm / h for 3CV to wash out the unbound materials until the UV detection value drops to the initial value;
[0130] 5) Elute the target protein with NTA-300 at a speed of 60 cm / h for 3 CV, and collect the eluted fractions;
[0131] 5) Elute with NTA-400 buffer at a speed of 60 cm / h for 3CV to elute all the proteins on the column;
[0132] 6) Wash the column with at least 2 CV of 1 M NaOH at a speed of 60 cm / h to remove residual contaminants in the packed column, such as lipids, endotoxins, nucleic acids, etc.;
[0133] 7) Wash the column with 5-10 CV of distilled water at a rate of 60 cm / h until the pH of the effluent is neutral and Cond is close to 0 to remove 1 M NaOH;
[0134] 8) Wash and store with 3CV of 20% ethanol at a speed of 60cm / h to prevent microbial growth.
[0135] The electrophoresis results are as follows Figure 5As shown, the affinity chromatography method can separate most of the target protein, and compared with the optimization (Example 4), the target protein band concentration is more concentrated after the purification procedure is optimized (Example 3), and the tailing is reduced, indicating that the optimized method has a better purification effect. It can be seen that the present invention optimizes the system flow rate, simplifies some operations, and improves the purification efficiency; optimizes the pH value of the buffer, which is beneficial to the stability of the target protein and slightly improves the protein purification effect.
[0136] Test Case
[0137] This test example tests the repair activity of recombinant fibronectin.
[0138] The recombinant fibronectin purified in Example 3 was used to perform a cell scratch experiment to detect the repair activity of the recombinant fibronectin. Hacat cells in the logarithmic growth phase were inoculated into a 24-well plate at a density of 2.5×10^5 cells / well and cultured in a carbon dioxide incubator at 37°C for 24 hours. After the cells were basically grown, a cross was made in the 24-well plate with a gun tip, and then the plate was washed once with PBS. The diluted samples (the control group samples were PBS buffer, and the experimental group samples were 0.4% recombinant fibronectin and 4.0% recombinant fibronectin, respectively) were added to the wells, 500 μL was added to each well, and the wells were cultured in a carbon dioxide incubator at 37°C for 24 hours. After that, the width of the scratches was measured under a microscope and photographed.
[0139] The results are as follows Figure 6 As shown, after being treated with 0.4% and 4% recombinant fibronectin, the scratch healing rate of Hacat cells reached more than 40%, which was significantly higher than 21% of the control group, indicating that recombinant fibronectin can significantly improve the migration and repair ability of Hacat cells.
[0140] In summary, the present invention constructs an engineered bacterium that produces high-yield recombinant fibronectin and designs a purification process to achieve efficient production of highly active recombinant fibronectin.
[0141] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.
Claims
1. A nucleic acid encoding a recombinant fibronectin, characterized in that: The sequence of the nucleic acid encoding the recombinant fibronectin includes the sequence shown in SEQ ID NO.
1.
2. A recombinant vector, characterized in that: The recombinant vector contains the nucleic acid encoding the recombinant fibronectin according to claim 1.
3. The recombinant vector according to claim 2, characterized in that The starting vector of the recombinant expression vector includes a pPIC9K vector.
4. An engineered bacterium expressing recombinant fibronectin, characterized in that: The engineered bacteria express recombinant fibronectin; The sequence of the nucleic acid encoding the recombinant fibronectin includes the sequence shown in SEQ ID NO.
1.
5. The engineered bacteria expressing recombinant fibronectin according to claim 4, characterized in that: The starting strain of the engineering bacteria includes Pichia pastoris; Preferably, the Pichia pastoris comprises Pichia pastoris GS115; Preferably, the encoding nucleic acid of the recombinant fibronectin is located in a recombinant expression vector; Preferably, the starting vector of the recombinant expression vector includes a pPIC9K vector.
6. The engineered bacteria expressing recombinant fibronectin according to claim 4 or 5, characterized in that: The copy number of the nucleic acid encoding the recombinant fibronectin in the engineered bacteria is 4 to 6 copies.
7. A method for constructing an engineered bacterium expressing recombinant fibronectin according to any one of claims 4 to 6, characterized in that: The construction method comprises: The encoding nucleic acid of the recombinant fibronectin is inserted into the starting vector to obtain the recombinant vector, and the recombinant vector is introduced into the starting strain to obtain the engineered bacteria expressing the recombinant fibronectin.
8. Use of the engineered bacteria expressing recombinant fibronectin according to any one of claims 4 to 6 in producing recombinant fibronectin.
9. A method for producing recombinant fibronectin, characterized in that: The production method comprises: Fermentation culture of the engineered bacteria expressing recombinant fibronectin according to any one of claims 4 to 6, collecting the fermentation broth, and performing product purification treatment to obtain the recombinant fibronectin.
10. The method for producing recombinant fibronectin according to claim 9, characterized in that: The product purification treatment includes sequentially subjecting the fermentation broth to affinity chromatography and molecular sieve chromatography; Preferably, the filler of the affinity chromatography comprises Ni-IDA and / or Ni-NTA; Preferably, the affinity chromatography buffer comprises NTA-5 buffer and NTA-400 buffer, wherein the NTA-5 buffer contains 4.5-5.5 mM imidazole, 19-21 mM Tris and 140-160 mM NaCl, with a pH of 7-9.5, and the NTA-400 buffer contains 380-420 mM imidazole, 19-21 mM Tris and 140-160 mM NaCl, with a pH of 7-9.5; Preferably, the filler of the molecular sieve chromatography comprises at least one of dextran bead gel, agarose gel, polyacrylamide gel or Sephacryl gel; Preferably, the buffer for the molecular sieve chromatography contains 120-130 mM Na2HPO4 and 14-16 mM NaCl, and the pH is 7-9.5.
Citation Information
Patent Citations
Recombinant fibronectin mutant and application thereof
CN111454350A
Coding sequence of fibronectin mutant with high expression quantity and strong activity and application of coding sequence
CN112941081A
High-expression and high-activity fibronectin mutant and application thereof
CN116063459A
Recombinant human fibronectin as well as preparation method and application thereof
CN118546240A
A novel polypeptide - type ii fibronectin 10 and a polynucleotide encoding the same
WO2001048000A1
Cited By
Coding gene of OBP2A protein and application thereof
CN121227716A
